A multicenter phase II trial of nab‐paclitaxel and capecitabine in HER‐2 negative and triple‐ negative advanced breast cancer: Could be an old regimen a valid approach to a changing disease?
Keyword(s):
Phase Ii
◽
2005 ◽
Vol 23
(16_suppl)
◽
pp. 876-876
◽